0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover182.84%IV-89.87%PremiumAug 16, 2024Expiry Date3.55Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8646Delta0.1203Gamma1.10Leverage Ratio-0.0076Theta-0.0032Rho-0.95Eff Leverage0.0022Vega
Aldeyra Therapeutics Stock Discussion
NEWS
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
Positive
Enrollment of the first patient in the Phase 3 clinical trial for reproxalap indicates progress in Aldeyra Therapeutics' efforts to address dry eye disease.
Potential resubmission of the NDA for reproxalap in the second half of 2024 demonstrates the company's commitment to advancing in...
Grabar Law Office is investigating claims on behalf of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shareholders. The investigation concerns whether certain officers of Aldeyra have breached their fiduciary duties owed to the company.
Current Aldeyra shareholders who have continuously held Aldeyra shares since prior to Januar...
• As a result, AbbVie (ABBV) is paying a non-refundable $5M option extension fee.
• The original option agreement was signed in late October.
• AbbVie (ABBV) now can exercise its option by the earlier of (a) the 10th business day after ...
No comment yet